Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q1 2026 GAAP revenue fell 12% to $530.2 million; net income $30.1 million

Mixed Impact 3 of 5 earnings Written later

ICU Medical reported first quarter 2026 results on May 7, 2026. GAAP revenue fell 12% year over year to $530.2 million, mainly due to the May 1, 2025 divestiture of its IV Solutions business, while GAAP net income swung to $30.1 million from a $15.5 million loss, helped by a $33.4 million tax benefit. The filing does not include new full-year guidance, and adjusted EBITDA was roughly flat at $98.7 million.

Key points

  • GAAP revenue was $530.2 million, down from $604.7 million; non-GAAP organic revenue rose 1% excluding the IV Solutions divestiture and foreign currency.
  • GAAP net income was $30.1 million, or $1.20 per diluted share, versus a net loss of $15.5 million, or $0.63 per share, a year earlier.
  • Adjusted diluted EPS was $1.97, up from $1.72; adjusted EBITDA was $98.7 million, versus $99.4 million.
  • Free cash flow was $27.6 million, down from $36.7 million, and cash and cash equivalents were $288.3 million at March 31, 2026.

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECMay 7, 2026, 4:11 PM ET
Accession number0000883984-26-000028

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.